Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
77.15(c) 79.49(c) 81.07(c) 81.17(c) 81.15(c) Last
13 075 461 15 577 149 11 465 505 9 893 617 7 523 056 Volume
-1.51% +3.03% +1.99% +0.12% -0.02% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 48 235 M - -
Net income 2021 13 308 M - -
Net Debt 2021 17 557 M - -
P/E ratio 2021 17,1x
Yield 2021 3,19%
Sales 2022 53 498 M - -
Net income 2022 16 172 M - -
Net Debt 2022 12 491 M - -
P/E ratio 2022 13,5x
Yield 2022 3,48%
Capitalization 205 B 205 B -
EV / Sales 2021 4,62x
EV / Sales 2022 4,07x
Nbr of Employees 73 500
Free-Float 70,7%
More Financials
Company
Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and... 
Sector
Pharmaceuticals
Calendar
10/28Earnings Release
More about the company
Ratings of Merck & Co., Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about MERCK & CO., INC.
10/22MERCK : Secures European Commission's Approval for Keytruda as Breast Cancer Treatment in ..
MT
10/22MERCK : European Commission Approves Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy a..
BU
10/22European Commission Approves Merck?s KEYTRUDA? (pembrolizumab) Plus Chemotherapy as Tre..
CI
10/22Merck Gets European OK for Keytruda in Triple-Negative Breast Cancer
DJ
10/22MODERNA : European Medicines Agency's Review for Moderna's COVID-19 Booster Shot Expected ..
MT
10/21MERCK : CDC ACIP Unanimously Votes to Provisionally Recommend Merck's VAXNEUVANCE (Pneumoc..
AQ
10/21MERCK : Bristol-Myers To Shed Acceleron Stake Ahead Of Merck & Co.'s $11.5 Billion Acquisi..
MT
10/20MERCK : British Government Secures COVID-19 Antivirals from Merck & Co., Pfizer
MT
10/20MERCK : CDC ACIP Unanimously Votes to Provisionally Recommend Merck's VAXNEUVANCE™ (..
BU
10/20CDC ACIP Unanimously Votes to Provisionally Recommend Merck?s VAXNEUVANCE?
CI
10/20U.K. in Agreements for Merck/Ridgeback, Pfizer Covid-19 Antivirals in Development
DJ
10/20MERCK : to Voluntarily Recall About 22,000 Cubicin Vials Due to Presence of Glass Particle..
MT
10/20MERCK : WHO Program To Acquire Merck & Co.'s COVID-19 Pill Under Aid Program
MT
10/19MERCK : Issues Voluntary Nationwide Recall of CUBICIN® (daptomycin for injection) 500 mg, ..
BU
10/19Merck & Co., Inc. Issues Voluntary Nationwide Recall of CUBICIN? (daptomycin for inject..
CI
More news
News in other languages on MERCK & CO., INC.
10/22MERCK : Keytruda approuvé par l'UE dans le cancer du sein
10/21Mientras PayPal se engancha a Pinterest, Evergrande reaparece
10/21Bristol-Myers va céder sa participation dans Acceleron avant l'acquisition de 11,5 mill..
10/20Le gouvernement britannique obtient les antiviraux COVID-19 de Merck & Co. et Pfizer
10/20CORONA-BLOG/Gates-Stiftung kündigt Investition von 120 Mio USD in Covid-Medikamente an
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 81,15 $
Average target price 94,79 $
Spread / Average Target 16,8%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-0.79%205 421
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.16.44%241 985
ELI LILLY AND COMPANY44.37%220 979